Skip to main content
Previous Poster Home Next

MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib in Combination with Pembrolizumab in Patients with FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma
07:30am - 03:45pm EST - March 31, 2023

  • Information
  • Resources
  • Play Recording

MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib in Combination with Pembrolizumab in Patients with FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma icon

https://jnccn.org/view/journal...


Author(s):
  • Nguyen H. Tran, MD, Assistant Professor of Oncology, Mayo Clinic Comprehensive Cancer Center

Tags: Member Institution Clinical Oncology ORP

Display Label Action
NCCN_poster_final.pdf Download Handout
AC23P29 - MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib in Combination with Pembrolizumab in Patients with FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma Download MP3